Adocia
About
History
Management
Board of directors
Advisory board
Products and platforms
Pipeline
Technology Platforms
Careers
The « Adocians »
HR policy
Work environment
Join us
Partnering
Investors
Media
Contact
Contact us
Map and accessibility
Investors
Regulated information
Stock information
Corporate governance
General meeting
Media
Press releases
Media
EN
FR
Number of shares and voting rights of ADOCIA as of September 30, 2018
Previous article
“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
Next article
“BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
